Receptor News and Research

RSS

Combined oral anticoagulant and antiplatelet therapy linked to poor prognosis in atrial fibrillation

Combined oral anticoagulant and antiplatelet therapy is associated with a worse prognosis than anticoagulation alone in newly diagnosed atrial fibrillation patients without a clear indication for antiplatelets, according to late breaking results from the GARFIELD-AF registry presented today at ESC Congress 2018.

28 Aug 2018

Blood pressure medication slows enlargement of the aorta in patients with Marfan syndrome

Treatment with a drug to lower blood pressure slows enlargement (dilatation) of the aorta in children and young adults with Marfan syndrome, according to late breaking results from the AIMS trial presented today in a Hot Line Session at ESC Congress 2018.

28 Aug 2018

Taking vacations could prolong life, suggests new study

Taking vacations could prolong life. That's the finding of a 40-year study presented today at ESC Congress and accepted for publication in The Journal of Nutrition, Health & Aging.

28 Aug 2018

Research solves mystery on nature of EGFR signaling and how it drives development

What do cancer and the growing legs of a fruit fly have in common? They can both be influenced by a single molecule, a protein that tends to call the shots inside of embryos as they develop into living, breathing animals.

28 Aug 2018

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Adding another inhibitor to therapies that cut off a tumor's access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.

27 Aug 2018

New personalized cellular therapy approved for use in the European Union

The European Commission has approved a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, making it the first chimeric antigen receptor (CAR) T cell therapy permitted for use in the European Union in two distinct indications.

27 Aug 2018

Discovery will allow scientists to target hypoxia in cancer

Researchers have discovered a new GPCR that will allow them to target hypoxia in cancer, offering a new, less harmful treatment for patients.

27 Aug 2018

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.

27 Aug 2018

Newly discovered target may prevent progression of liver injury to cancer

Problems like obesity and alcoholism appear to chronically trigger in the liver a receptor known to amplify inflammation in response to invaders like bacteria, scientists report.

27 Aug 2018

$Entresto drug can be initiated early and safely in heart failure patients with reduced ejection fraction$

Entresto drug can be initiated early and safely in heart failure patients with reduced ejection fraction

Data from the TRANSITION study presented today at the European Society of Cardiology Congress in Munich, Germany has shown that Entresto® can be initiated early and safely in a wide range of heart failure patients with reduced ejection fraction who have been stabilized after hospitalization due to an acute heart failure episode.

25 Aug 2018

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Forbius announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas.

25 Aug 2018

Changes in TRPV3 genes may have helped mammoths withstand lower temperatures

Columbia University biomedical researchers have captured close-up views of TRPV3, a skin-cell ion channel that plays important roles in sensing temperature, itch, and pain.

25 Aug 2018

Proteins that protect neurons from destruction can be delivered through nose

Protective proteins that mitigate the destruction of nerve cells after a stroke can be administered into the brain through the nose, as Heidelberg University researchers demonstrated using a mouse model.

24 Aug 2018

Researchers take major step in eliminating cancer without harming healthy tissue

A major advance towards targeting cancer without harming healthy tissue has been discovered by University of Bristol researchers.

24 Aug 2018

MDA announces 34 new grants totaling $9.9 million to accelerate neuromuscular research

The Muscular Dystrophy Association today announced the award of 34 new grants totaling more than $9.9 million for its summer round of funding. These new grants represent a continued commitment by MDA to fund groundbreaking research that will accelerate treatments and cures for the more than 40 diseases in its program.

24 Aug 2018

'Plastic antibodies' effectively target and eliminate tumor cells

A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or "plastic antibodies." NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells.

23 Aug 2018

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

23 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

I-antigen plays major role in glycan-mediated processes, shows study

Two new studies have unveiled how a peculiar molecule impacts how antibody-producing cells develop and function as well as how normal melanocytes progress to melanoma malignancy.

23 Aug 2018

Scientists discover how a protein in the brain maintains 'energy rheostasis'

Scientists at the University of Michigan and Vanderbilt University have identified the function of a protein that has been confounding metabolism researchers for more than two decades. And it may have implications both for treating obesity and for understanding weight gain during pregnancy and menopause.

23 Aug 2018

Receptor News and Research

Combined oral anticoagulant and antiplatelet therapy linked to poor prognosis in atrial fibrillation

Blood pressure medication slows enlargement of the aorta in patients with Marfan syndrome

Taking vacations could prolong life, suggests new study

Research solves mystery on nature of EGFR signaling and how it drives development

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

New personalized cellular therapy approved for use in the European Union

Discovery will allow scientists to target hypoxia in cancer

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

Newly discovered target may prevent progression of liver injury to cancer

Entresto drug can be initiated early and safely in heart failure patients with reduced ejection fraction

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Changes in TRPV3 genes may have helped mammoths withstand lower temperatures

Proteins that protect neurons from destruction can be delivered through nose

Researchers take major step in eliminating cancer without harming healthy tissue

MDA announces 34 new grants totaling $9.9 million to accelerate neuromuscular research

'Plastic antibodies' effectively target and eliminate tumor cells

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

I-antigen plays major role in glycan-mediated processes, shows study

Scientists discover how a protein in the brain maintains 'energy rheostasis'

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News